{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:57:10Z","timestamp":1790744230002,"version":"4.1.0"},"reference-count":148,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["33286-2025"],"award-info":[{"award-number":["33286-2025"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"award":["33286-2025"],"award-info":[{"award-number":["33286-2025"]}],"id":[{"id":"https:\/\/ror.org\/02g2x7380","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Conventional chemotherapeutics often suffer from poor aqueous solubility, short circulation half-lives, lack of tumor selectivity, and present dose-limiting systemic toxicity. This perspective examines the Trojan Horse Approach (THA), in which plasma carrier proteins (PCPs) are exploited as discrete, non-covalent supramolecular hosts for chemotherapeutic agents, and discusses its potential to overcome the limitations of both free drugs and conventional protein nanoparticles. Two principal strategies for assembling ex vivo drug\u2013protein complexes are discussed: (i) molecular recognition, in which drugs occupy native ligand-binding pockets, and (ii) molecular anchoring, in which drugs are conjugated to high-affinity anchor ligands. The perspective critically assesses the current state of the art, distinguishes different levels of experimental validation, and discusses the major limitations and barriers to clinical translation. Structural, biochemical, and pharmacological evidence is examined for human serum albumin, transferrin, transthyretin, alpha-1-acid glycoprotein, alpha-fetoprotein, lactoferrin, and other plasma proteins. When appropriately designed and validated, protein-based complexes may preserve the native protein structure while conferring improved drug solubility, protection from premature metabolism, prolonged systemic circulation and enhanced tumor accumulation via combined passive and active targeting. PCPs represent a versatile and underexploited toolbox for cancer drug delivery. Expanding the repertoire of protein carriers, applying in silico rational design to guide the selection and optimization of drug\u2013protein complexes, and exploring the use of patient-derived autologous proteins may open new opportunities for more effective and personalized therapies.<\/jats:p>","DOI":"10.3390\/cancers18193106","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:29:53Z","timestamp":1790267393000},"page":"3106","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma Carrier Proteins as Supramolecular Nanovectors for Cancer Therapy: The Trojan Horse Approach"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-2211","authenticated-orcid":false,"given":"Alessia","family":"Marconi","sequence":"first","affiliation":[{"name":"Preclinical & Translational Research in Oncology Lab (PRO), IRCCS Azienda Ospedaliero\u2014Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-4645","authenticated-orcid":false,"given":"Andrea","family":"Carboni","sequence":"additional","affiliation":[{"name":"Preclinical & Translational Research in Oncology Lab (PRO), IRCCS Azienda Ospedaliero\u2014Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Dipartimento di Chimica \u201cGiacomo Ciamician\u201d, Alma Mater Studiorum\u2014Universit\u00e0 di Bologna, Via Piero Gobetti, 85, 40129 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-298X","authenticated-orcid":false,"given":"Matteo","family":"Di Giosia","sequence":"additional","affiliation":[{"name":"Preclinical & Translational Research in Oncology Lab (PRO), IRCCS Azienda Ospedaliero\u2014Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Dipartimento di Chimica \u201cGiacomo Ciamician\u201d, Alma Mater Studiorum\u2014Universit\u00e0 di Bologna, Via Piero Gobetti, 85, 40129 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9583-2146","authenticated-orcid":false,"given":"Matteo","family":"Calvaresi","sequence":"additional","affiliation":[{"name":"Preclinical & Translational Research in Oncology Lab (PRO), IRCCS Azienda Ospedaliero\u2014Universitaria di Bologna, 40138 Bologna, Italy"},{"name":"Dipartimento di Chimica \u201cGiacomo Ciamician\u201d, Alma Mater Studiorum\u2014Universit\u00e0 di Bologna, Via Piero Gobetti, 85, 40129 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.talanta.2011.08.034","article-title":"Analysis of Anticancer Drugs: A Review","volume":"85","author":"Nussbaumer","year":"2011","journal-title":"Talanta"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","article-title":"Cardiotoxicity of Anticancer Treatments: What the Cardiologist Needs to Know","volume":"7","author":"Ewer","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2012.07.010","article-title":"Analysis on the Current Status of Targeted Drug Delivery to Tumors","volume":"164","author":"Kwon","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-022-01250-1","article-title":"Recent Advances in Developing Active Targeting and Multi-Functional Drug Delivery Systems via Bioorthogonal Chemistry","volume":"7","author":"Yi","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e10421","DOI":"10.1002\/btm2.10421","article-title":"Micro and Nanotechnologies: The Little Formulations That Could","volume":"8","author":"Stiepel","year":"2022","journal-title":"Bioeng. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rana, A., Adhikary, M., Singh, P.K., Das, B.C., and Bhatnagar, S. (2023). \u201cSmart\u201d Drug Delivery: A Window to Future of Translational Medicine. Front. Chem., 10.","DOI":"10.3389\/fchem.2022.1095598"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jconrel.2011.11.028","article-title":"Clinical Impact of Serum Proteins on Drug Delivery","volume":"161","author":"Kratz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1907256","DOI":"10.1002\/smll.201907256","article-title":"Protein-Based Artificial Nanosystems in Cancer Therapy","volume":"16","author":"Zhang","year":"2020","journal-title":"Small"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/annonc\/mdl104","article-title":"Abraxane\u00ae, a Novel Cremophor\u00ae-Free, Albumin-Bound Particle Form of Paclitaxel for the Treatment of Advanced Non-Small-Cell Lung Cancer","volume":"17","author":"Green","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1186\/bcr2282","article-title":"Nab-Paclitaxel (Abraxane\u00ae): An Albumin-Bound Cytotoxic Exploiting Natural Delivery Mechanisms into Tumors","volume":"11","author":"Garber","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00280-015-2833-5","article-title":"Albumin-Bound Nanoparticle (Nab) Paclitaxel Exhibits Enhanced Paclitaxel Tissue Distribution and Tumor Penetration","volume":"76","author":"Chen","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Desai, N. (2016). Nanoparticle Albumin-Bound Paclitaxel (Abraxane\u00ae). Albumin in Medicine: Pathological and Clinical Applications, Springer.","DOI":"10.1007\/978-981-10-2116-9_6"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.23.02266","article-title":"Phase II Trial of Nab- Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update","volume":"42","author":"Wagner","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_14","unstructured":"Wagner, A.J. (2024, January 12). Prospective Studies in Ultra-Rare Sarcomas: Nab-Sirolimus in PEComa as an Example. Proceedings of the EMA\/EORTC Soft Tissue and Bone Sarcoma Group Joint Workshop, Online."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2104012","DOI":"10.1002\/advs.202104012","article-title":"Protein Nanoparticles: Uniting the Power of Proteins with Engineering Design Approaches","volume":"9","author":"Habibi","year":"2022","journal-title":"Adv. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.2174\/1381612822666160209152446","article-title":"Nanoparticles Based on Plasma Proteins for Drug Delivery Applications","volume":"22","author":"Tezcaner","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-3-319-16241-6_10","article-title":"Nanoparticle Albumin-Bound Anticancer Agents","volume":"Volume 20","author":"Desai","year":"2015","journal-title":"Non-Biological Complex Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2614801","DOI":"10.1080\/10717544.2026.2614801","article-title":"The Colloidal Stability of Albumin-Based Drug Delivery Systems Has a Profound Effect on Tumoricidal Activity","volume":"33","author":"Xiong","year":"2026","journal-title":"Drug Deliv."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ferraro, C., Dattilo, M., Patitucci, F., Prete, S., Scopelliti, G., Parisi, O.I., and Puoci, F. (2024). Exploring Protein-Based Carriers in Drug Delivery: A Review. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16091172"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/accountsmr.1c00065","article-title":"Incorporation of Molecular Nanoparticles Inside Proteins: The Trojan Horse Approach in Theranostics","volume":"2","author":"Zerbetto","year":"2021","journal-title":"Acc. Mater. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9908","DOI":"10.1039\/C8NR02220H","article-title":"Proteins as Supramolecular Hosts for C60: A True Solution of C60 in Water","volume":"10","author":"Bomans","year":"2018","journal-title":"Nanoscale"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1039\/c1nr10082c","article-title":"Fullerene Sorting Proteins","volume":"3","author":"Calvaresi","year":"2011","journal-title":"Nanoscale"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cantelli, A., Malferrari, M., Mattioli, E.J., Marconi, A., Mirra, G., Sold\u00e0, A., Marforio, T.D., Zerbetto, F., Rapino, S., and Di Giosia, M. (2022). Enhanced Uptake and Phototoxicity of C60@albumin Hybrids by Folate Bioconjugation. Nanomaterials, 12.","DOI":"10.3390\/nano12193501"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1021\/nn901809b","article-title":"Baiting Proteins with C60","volume":"4","author":"Calvaresi","year":"2010","journal-title":"ACS Nano"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1021\/nn4063374","article-title":"C60@Lysozyme: Direct Observation by Nuclear Magnetic Resonance of a 1:1 Fullerene Protein Adduct","volume":"8","author":"Calvaresi","year":"2014","journal-title":"ACS Nano"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"139798","DOI":"10.1016\/j.jcis.2025.139798","article-title":"Structural Determinants Underlying the Supramolecular Binding between Carborane and Proteins in Water","volume":"708","author":"Marforio","year":"2026","journal-title":"J. Colloid Interface Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/10717549809065759","article-title":"Serum Proteins as Drug Carriers of Anticancer Agents: A Review","volume":"5","author":"Kratz","year":"1998","journal-title":"Drug Deliv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1248\/cpb.c23-00535","article-title":"Targeted Therapy for Prostate Cancer by Prostate-Specific Membrane Antigen-Targeted Small-Molecule Drug Conjugates","volume":"72","author":"Nakajima","year":"2024","journal-title":"Chem. Pharm. Bull."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ejmech.2018.12.035","article-title":"Small Molecule-Drug Conjugates: A Novel Strategy for Cancer-Targeted Treatment","volume":"163","author":"Zhuang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15473","DOI":"10.1021\/acs.jmedchem.2c01423","article-title":"Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Conjugates by Linker Stabilization and Conjugation to Transthyretin Ligand","volume":"65","author":"Amin","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"118593","DOI":"10.1016\/j.biopha.2025.118593","article-title":"Recent Developments in Bioconjugation: From Strategies to Design and Clinical Applications","volume":"192","author":"Samieipour","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"188655","DOI":"10.1016\/j.bbcan.2021.188655","article-title":"Systematic Interaction of Plasma Albumin with the Efficacy of Chemotherapeutic Drugs","volume":"1877","author":"Yu","year":"2022","journal-title":"Biochim. Biophys. Acta\u2014Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/cbdd.12501","article-title":"Binding and Anticancer Properties of Plumbagin with Human Serum Albumin","volume":"86","author":"Gou","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jmb.2005.07.075","article-title":"Structural Basis of the Drug-Binding Specificity of Human Serum Albumin","volume":"353","author":"Ghuman","year":"2005","journal-title":"J. Mol. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/0929866529666220426124834","article-title":"Binding Sites of Anticancer Drugs on Human Serum Albumin (HSA): A Review","volume":"29","author":"Molaei","year":"2022","journal-title":"Protein Pept. Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1080\/17425247.2022.2134341","article-title":"Current Trends in the Use of Human Serum Albumin for Drug Delivery in Cancer","volume":"19","author":"Paul","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1016\/j.bbagen.2013.06.032","article-title":"Structural Studies of Several Clinically Important Oncology Drugs in Complex with Human Serum Albumin","volume":"1830","author":"Wang","year":"2013","journal-title":"Biochim. Biophys. Acta-Gen. Subj."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100114","DOI":"10.1016\/j.crstbi.2023.100114","article-title":"Unraveling the Versatility of Human Serum Albumin\u2014A Comprehensive Review of Its Biological Significance and Therapeutic Potential","volume":"6","author":"Ashraf","year":"2023","journal-title":"Curr. Res. Struct. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/138620710790596745","article-title":"Plasma Protein Binding in Drug Discovery and Development","volume":"13","author":"Howard","year":"2010","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1039\/C9MD00018F","article-title":"Non-Covalent Albumin-Binding Ligands for Extending the Circulating Half-Life of Small Biotherapeutics","volume":"10","author":"Zorzi","year":"2019","journal-title":"Medchemcomm"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/17425255.2020.1801633","article-title":"Albumin-Based Drug Designs for Pharmacokinetic Modulation","volume":"16","author":"Pilati","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1021\/acsbiomaterials.8b01098","article-title":"Protein Nanoparticles: Promising Platforms for Drug Delivery Applications","volume":"4","author":"Jain","year":"2018","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1039\/C5CS00158G","article-title":"Simple Bioconjugate Chemistry Serves Great Clinical Advances: Albumin as a Versatile Platform for Diagnosis and Precision Therapy","volume":"45","author":"Liu","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2165\/00003088-199426010-00004","article-title":"Drug Binding in Plasma","volume":"26","author":"Urien","year":"1994","journal-title":"Clin. Pharmacokinet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2174\/1389203718666171002115547","article-title":"Chemotherapeutic Drugs and Plasma Proteins: Exploring New Dimensions","volume":"19","author":"Zia","year":"2018","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Keen, P. (1971). Effect of Binding to Plasma Proteins on the Distribution, Activity and Elimination of Drugs. Concepts in Biochemical Pharmacology, Springer.","DOI":"10.1007\/978-3-642-65052-9_10"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1517\/17425247.2013.805200","article-title":"Proteins: Emerging Carrier for Delivery of Cancer Therapeutics","volume":"10","author":"Yewale","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.xphs.2019.07.002","article-title":"\u03b11-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents","volume":"108","author":"Matsusaka","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/13543776.12.3.433","article-title":"Drug Conjugates with Albumin and Transferrin","volume":"12","author":"Kratz","year":"2002","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Waller, D.G., and Sampson, A.P. (2018). Pharmacokinetics. Medical Pharmacology and Therapeutics, Elsevier.","DOI":"10.1016\/B978-0-7020-7167-6.00002-6"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10475","DOI":"10.1021\/acs.jmedchem.9b00511","article-title":"Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting","volume":"62","author":"Ahmad","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jconrel.2014.03.013","article-title":"A Clinical Update of Using Albumin as a Drug Vehicle\u2014A Commentary","volume":"190","author":"Kratz","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Cho, H., Jeon, S.I., Ahn, C.H., Shim, M.K., and Kim, K. (2022). Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14040728"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing Albumin as a Carrier for Cancer Therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.1002\/adma.201600038","article-title":"Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise","volume":"28","author":"Chen","year":"2016","journal-title":"Adv. Mater."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1517\/17425247.2015.993313","article-title":"Albumin and Its Application in Drug Delivery","volume":"12","author":"Sleep","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2174\/1381612821666150302114739","article-title":"Evaluation of Interactions Between Platinum-\/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs","volume":"21","author":"Gou","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Rubio-Camacho, M., Encinar, J.A., Mart\u00ednez-Tom\u00e9, M.J., Esquembre, R., and Mateo, C.R. (2020). The Interaction of Temozolomide with Blood Components Suggests the Potential Use of Human Serum Albumin as a Biomimetic Carrier for the Drug. Biomolecules, 10.","DOI":"10.3390\/biom10071015"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.saa.2017.03.059","article-title":"Comprehensive Insight into the Binding of Sunitinib, a Multi-Targeted Anticancer Drug to Human Serum Albumin","volume":"181","author":"Kabir","year":"2017","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Marconi, A., Mattioli, E.J., Ingargiola, F., Giugliano, G., Marforio, T.D., Prodi, L., Di Giosia, M., and Calvaresi, M. (2023). Dissecting the Interactions between Chlorin E6 and Human Serum Albumin. Molecules, 28.","DOI":"10.3390\/molecules28052348"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1021\/mp400027q","article-title":"Subdomain IB Is the Third Major Drug Binding Region of Human Serum Albumin: Toward the Three-Sites Model","volume":"10","author":"Zsila","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2070025","DOI":"10.1002\/adtp.202070025","article-title":"Single Protein Encapsulation: Single Protein Encapsulated Doxorubicin as an Efficacious Anticancer Therapeutic (Adv. Therap. 11\/2020)","volume":"3","author":"Yu","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1186\/s12967-023-04778-0","article-title":"Single Protein Encapsulated SN38 for Tumor-Targeting Treatment","volume":"21","author":"Yu","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e23534","DOI":"10.1200\/JCO.2026.44.16_suppl.e23534","article-title":"Cardiotoxicity and Efficacy Outcomes of SPEDOX-6 for Targeted Treatment of Soft Tissue Sarcomas","volume":"44","author":"Yu","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1158\/1538-7445.AM2026-3903","article-title":"Abstract 3903: SPEDOX-6: First-in-Human Phase IB\/IIA Trial on Soft Tissue Sarcomas","volume":"86","author":"Yu","year":"2026","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijpharm.2014.03.044","article-title":"Enhanced Delivery of Artemisinin and Its Analogues to Cancer Cells by Their Adducts with Human Serum Transferrin","volume":"467","author":"Yang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e2728","DOI":"10.1002\/jmr.2728","article-title":"Investigating the Interaction of Anticancer Drug Temsirolimus with Human Transferrin: Molecular Docking and Spectroscopic Approach","volume":"31","author":"Shamsi","year":"2018","journal-title":"J. Mol. Recognit."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"123569","DOI":"10.1016\/j.saa.2023.123569","article-title":"Tracking the Binding Site of Anticancer Drug Fluxoridin with Fe-Related Proteins to Achieve Intelligent Drug Delivery","volume":"306","author":"Shahraki","year":"2024","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.saa.2016.09.041","article-title":"Interaction of Imatinib Mesylate with Human Serum Transferrin: The Comparative Spectroscopic Studies","volume":"173","year":"2017","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"136874","DOI":"10.1016\/j.ijbiomac.2024.136874","article-title":"Spectroscopic Study and in Vitro Anticancer Effect toward Colorectal Cancer Cells of a Hydroxyaurone Leptosidin Compound Complexed with Transferrin","volume":"282","author":"Lv","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/rcm.2010","article-title":"Intact Human Holo-Transferrin Interaction with Oxaliplatin","volume":"19","author":"Zhao","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ijbiomac.2010.08.002","article-title":"Investigation on the Interaction between Tamoxifen and Human Holo-Transferrin: Determination of the Binding Mechanism by Fluorescence Quenching, Resonance Light Scattering and Circular Dichroism Methods","volume":"47","author":"Sarzehi","year":"2010","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s11051-013-1929-2","article-title":"A Facile Drug Delivery System Preparation through the Interaction between Drug and Iron Ion of Transferrin","volume":"15","author":"Zhou","year":"2013","journal-title":"J. Nanopart. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1016\/j.bmcl.2011.07.066","article-title":"Constructing Transferrin Receptor Targeted Drug Delivery System by Using Doxorubicin Hydrochloride and Vanadocene Dichloride","volume":"21","author":"Zhang","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"152646","DOI":"10.1016\/j.ijbiomac.2026.152646","article-title":"Synergistic Effects of Lactoferrin in Enhancing Cisplatin Activity: From Molecular Interactions to Improved Drug Delivery Systems","volume":"368","author":"Pryshchepa","year":"2026","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1002\/fsn3.4479","article-title":"Structural and in Vitro Anticancer Properties of the Kaempferol\u2013Lactoferrin Complex","volume":"12","author":"Xue","year":"2024","journal-title":"Food Sci. Nutr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1021\/acs.chemrestox.9b00094","article-title":"Affinity and Effect of Anticancer Drugs on the Redox of Hemoglobin","volume":"32","author":"Puscas","year":"2019","journal-title":"Chem. Res. Toxicol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jphotobiol.2016.08.031","article-title":"Probing the Binding of Anticancer Drug Topotecan with Human Hemoglobin: Structural and Thermodynamic Studies","volume":"163","author":"Khan","year":"2016","journal-title":"J. Photochem. Photobiol. B"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1080\/07391102.2016.1176958","article-title":"A Comparative Spectroscopic and Calorimetric Investigation of the Interaction of Amsacrine with Heme Proteins, Hemoglobin and Myoglobin","volume":"35","author":"Bhowmik","year":"2017","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1021\/cr040704h","article-title":"Interactions of Antitumor Metallodrugs with Serum Proteins: Advances in Characterization Using Modern Analytical Methodology","volume":"106","author":"Timerbaev","year":"2006","journal-title":"Chem. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jpba.2016.12.001","article-title":"Interaction of Anticancer Drug Clofarabine with Human Serum Albumin and Human \u03b1-1 Acid Glycoprotein. Spectroscopic and Molecular Docking Approach","volume":"135","author":"Ajmal","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molstruc.2016.02.048","article-title":"Interaction of the Recently Approved Anticancer Drug Nintedanib with Human Acute Phase Reactant \u03b1 1-Acid Glycoprotein","volume":"1115","author":"Abdelhameed","year":"2016","journal-title":"J. Mol. Struct."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"106651","DOI":"10.1016\/j.ejps.2023.106651","article-title":"In Vitro Biodistribution Studies on Clinically Approved FGFR Inhibitors Ponatinib, Nintedanib, Erlotinib and the Investigational Inhibitor KP2692","volume":"192","author":"Mathuber","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"124197","DOI":"10.1016\/j.saa.2024.124197","article-title":"In Vitro Investigation of the Binding Characteristics of Dacomitinib to Human \u03b1 1-Acid Glycoprotein: Multispectral and Computational Modeling","volume":"314","author":"Hu","year":"2024","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Huang, T., Wang, W.J., Huang, J.P., Chen, D., Gu, H., Shi, J.H., and Jiang, S.L. (2026). Exploring the Binding Behavior between RTK Inhibitor Sulfatinib and Human Alpha-1-Acid Glycoprotein (HAG): Multi-Spectroscopic Approaches and Computational Simulations. Spectrosc. Lett., 1\u201315.","DOI":"10.1080\/00387010.2026.2632336"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"121834","DOI":"10.1016\/j.saa.2022.121834","article-title":"Comprehending Binding Features between Ibrutinib and Human Alpha-1 Acid Glycoprotein: Combined Experimental Approaches and Theoretical Simulations","volume":"285","author":"Jiang","year":"2023","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/07391102.2023.2195015","article-title":"Insight into Intermolecular Binding Mechanism of Apatinib Mesylate and Human Alpha-1-Acid Glycoprotein: Combined Multi-Spectroscopic Approaches with in Silico","volume":"42","author":"Jiang","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Tamarit, L., El Ouardi, M., Lence, E., Andreu, I., Gonz\u00e1lez-Bello, C., Miranda, M.A., and Vay\u00e1, I. (2024). Modulation of the Photobehavior of Gefitinib and Its Phenolic Metabolites by Human Transport Proteins. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1387057"},{"key":"ref_89","first-page":"0011","article-title":"Here, There, and Everywhere: Alpha-Fetoprotein in Cancer Immunotherapy","volume":"2","author":"Pak","year":"2026","journal-title":"Cancer Res. Ther. Connect"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4155\/tde-2018-0068","article-title":"\u03b1-Fetoprotein-Binding Toxins and Teratogens Against Cancer","volume":"10","author":"Pak","year":"2019","journal-title":"Ther. Deliv."},{"key":"ref_91","unstructured":"Pak, V.N., Pak, N.A., Reshetnikov, S.S., Nikonov, S.D., and Ogirenko, A.P. (2025). Method of Treatment of Malignant Neoplasms and Complex Preparation Having Antineoplastic Activity for Use in Such Treatment. (US6878688B2), Available online: https:\/\/patents.google.com\/patent\/US6878688B2\/en."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0014-5793(99)00440-8","article-title":"Water-Soluble 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Complex with Human \u03b1-Fetoprotein: Properties, Toxicity in Vivo and Antitumor Activity in Vitro","volume":"450","author":"Sotnichenko","year":"1999","journal-title":"FEBS Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"16151","DOI":"10.18632\/oncotarget.3951","article-title":"Recombinant Human Alpha Fetoprotein Synergistically Potentiates the Anti-Cancer Effects of 1\u2019-S-1\u2019-Acetoxychavicol Acetate When Used as a Complex against Human Tumours Harbouring AFP-Receptors","volume":"6","author":"Arshad","year":"2015","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10517-017-3956-y","article-title":"Biodistribution of Alpha-Fetoprotein-Containing Noncovalent Complex Aimpila with Antitumor Activity","volume":"164","author":"Treshchalina","year":"2017","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1010428317734815","article-title":"Binding Characterization of the Targeting Drug AIMPILA to AFP Receptors in Human Tumor Xenografts","volume":"39","author":"Tcherkassova","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_96","unstructured":"Kotra, L.P., Paige, C.J., Bello, A.M., Sherman, I., and University Health Network (2016). Drug Complexes Comprising Alpha-Fetoprotein. (WO\/2016\/119045A1), Available online: https:\/\/patentimages.storage.googleapis.com\/0c\/a7\/ee\/1fd56e9fbcb392\/WO2016119045A1.pdf."},{"key":"ref_97","unstructured":"(2026, September 09). Alpha Fetoprotein (AFP)\u2014Alpha Cancer Technologies. Available online: https:\/\/alpha-cancer.com\/our-products\/alpha-fetoprotein\/."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Marconi, A., Giugliano, G., Di Giosia, M., Marforio, T.D., Trivini, M., Turrini, E., Fimognari, C., Zerbetto, F., Mattioli, E.J., and Calvaresi, M. (2023). Identification of Blood Transport Proteins to Carry Temoporfin: A Domino Approach from Virtual Screening to Synthesis and In Vitro PDT Testing. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030919"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Mattioli, E.J., Ulfo, L., Marconi, A., Pellicioni, V., Costantini, P.E., Marforio, T.D., Di Giosia, M., Danielli, A., Fimognari, C., and Turrini, E. (2023). Carrying Temoporfin with Human Serum Albumin: A New Perspective for Photodynamic Application in Head and Neck Cancer. Biomolecules, 13.","DOI":"10.3390\/biom13010068"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1021\/acsabm.0c00450","article-title":"Enhanced Photodynamic Therapy Using the Apohemoglobin-Haptoglobin Complex as a Carrier of Aluminum Phthalocyanine","volume":"3","author":"Pires","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0005-2795(80)90246-9","article-title":"The Interaction of Human Serum Albumin and Hemopexin with Porphyrins","volume":"624","author":"Morgan","year":"1980","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0304-3835(99)00367-5","article-title":"Hemopexin as a Carrier Protein of Tumor-Localizing Ga-Metalloporphyrin- ATN-2","volume":"149","author":"Nakajima","year":"2000","journal-title":"Cancer Lett."},{"key":"ref_103","first-page":"278","article-title":"Binding of Ceruloplasmin with Cationic Porphyrins: PH and Salt Composition of a Medium","volume":"Volume 11363","author":"Gyulkhandanyan","year":"2020","journal-title":"Tissue Optics and Photonics"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Gyulkhandanyan, A.G., Zakoyana, A.A., Gyulkhandanyan, A.G., Parkhots, M.V., Dzhagarov, B.M., Lazareva, E.N., Tuchin, V.V., and Gyulkhandanyana, G.V. (2019). Ceruloplasmin\u2014A Potential Carrier of Photosensitizers for Photodynamic Therapy of Tumors. Medical Laser Applications and Laser-Tissue Interactions IX (2019), SPIE.","DOI":"10.1117\/12.2527568"},{"key":"ref_105","first-page":"80","article-title":"The Effect of Light on the Oxidase Activity of Human Ceruloplasmin in Complexes with Cationic Zn-Porphyrins","volume":"61","author":"Zakoyan","year":"2021","journal-title":"Med. Sci. Arm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1021\/acs.bioconjchem.6b00487","article-title":"Albumin-Binding Evans Blue Derivatives for Diagnostic Imaging and Production of Long-Acting Therapeutics","volume":"27","author":"Jacobson","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"165724","DOI":"10.1016\/j.cej.2025.165724","article-title":"A Fatty Acid Modification Strategy to Improve the Binding Affinity of Epirubicin to Human Serum Albumin for Efficient Cancer Therapy","volume":"519","author":"Huang","year":"2025","journal-title":"Chem. Eng. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.7150\/thno.24382","article-title":"A Paclitaxel Prodrug with Bifunctional Folate and Albumin Binding Moieties for Both Passive and Active Targeted Cancer Therapy","volume":"8","author":"Shan","year":"2018","journal-title":"Theranostics"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1021\/acs.jmedchem.5c01560","article-title":"Two Sides of the Same Coin: Transthyretin (TTR) as a Target or Drug Carrier for Drug (Bio)Conjugates","volume":"69","author":"Russomanno","year":"2026","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1021\/acs.molpharmaceut.9b00432","article-title":"Hydrophilic Small Molecules That Harness Transthyretin To Enhance the Safety and Efficacy of Targeted Chemotherapeutic Agents","volume":"16","author":"Pal","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e202303202","DOI":"10.1002\/anie.202303202","article-title":"Combining Solid-State NMR with Structural and Biophysical Techniques to Design Challenging Protein-Drug Conjugates","volume":"62","author":"Cerofolini","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Merlot, A.M., Kalinowski, D.S., and Richardson, D.R. (2014). Unraveling the Mysteries of Serum Albumin-More than Just a Serum Protein. Front. Physiol., 5.","DOI":"10.3389\/fphys.2014.00299"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2020.08.015","article-title":"Controlled Loading of Albumin-Drug Conjugates Ex Vivo for Enhanced Drug Delivery and Antitumor Efficacy","volume":"328","author":"Liu","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jconrel.2025.01.035","article-title":"Albumin-Based Delivery Systems: Recent Advances, Challenges, and Opportunities","volume":"380","author":"Murphy","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2500011","DOI":"10.1002\/anbr.202500011","article-title":"Advances on Albumin-Based Carriers for Anticancer Drug Delivery","volume":"5","author":"Zhou","year":"2025","journal-title":"Adv. Nanobiomed Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s10856-015-5618-9","article-title":"Application of Albumin-Based Nanoparticles in the Management of Cancer","volume":"27","author":"Yu","year":"2015","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","article-title":"The Uniqueness of Albumin as a Carrier in Nanodrug Delivery","volume":"18","author":"Spada","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"126056","DOI":"10.1016\/j.ijpharm.2025.126056","article-title":"Albumin as a Natural and Moldable Biomaterial for Biomimetic Drug Delivery Applications","volume":"683","author":"Rochani","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Parodi, A., Miao, J., Soond, S.M., Rudzi\u0144ska, M., and Zamyatnin, A.A. (2019). Albumin Nanovectors in Cancer Therapy and Imaging. Biomolecules, 9.","DOI":"10.3390\/biom9060218"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.stemcr.2023.08.005","article-title":"Protein-Encapsulated Doxorubicin Reduces Cardiotoxicity in HiPSC-Cardiomyocytes and Cardiac Spheroids While Maintaining Anticancer Efficacy","volume":"18","author":"Arzt","year":"2023","journal-title":"Stem Cell Rep."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Yu, C., Huang, F., Wang, L., Liu, M., Chow, W.A., Ling, X., Li, F., Cook-Wiens, G., Li, L., and Cui, X. (2025). Targeted Treatment of Sarcomas by Single Protein Encapsulated Doxorubicin with Undetectable Cardiotoxicity and Superior Efficacy. Cancers, 17.","DOI":"10.3390\/cancers17050881"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4155\/tde.14.59","article-title":"The Use of \u03b1-Fetoprotein for the Delivery of Cytotoxic Payloads to Cancer Cells","volume":"5","author":"Pak","year":"2014","journal-title":"Ther. Deliv."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Jarockyte, G., Poderys, V., Barzda, V., Karabanovas, V., and Rotomskis, R. (2022). Blood Plasma Stabilized Gold Nanoclusters for Personalized Tumor Theranostics. Cancers, 14.","DOI":"10.3390\/cancers14081887"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/med.10008","article-title":"Transferrin\/Transferrin Receptor-Mediated Drug Delivery","volume":"22","author":"Li","year":"2002","journal-title":"Med. Res. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00232-014-9637-0","article-title":"Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy","volume":"247","author":"Tortorella","year":"2014","journal-title":"J. Membr. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/pr.54.4.561","article-title":"Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway","volume":"54","author":"Qian","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/kin.20449","article-title":"Kinetic and Thermodynamic Characterization of Camptothecin Hydrolysis at Physiological PH in the Absence and Presence of Human Serum Albumin","volume":"41","author":"Thakur","year":"2009","journal-title":"Int. J. Chem. Kinet."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1074\/jbc.M110.164848","article-title":"Extending Half-Life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain","volume":"286","author":"Andersen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1200\/jco.2007.25.18_suppl.3589","article-title":"Treatment of Metastatic Colorectal Cancer with Aimpila, a Glycoside\/Alpha-Fetoprotein Complex","volume":"25","author":"Pak","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1055\/s-2006-925348","article-title":"The Role of Plasma-Binding Proteins in the Cellular Uptake of Lipophilic Vitamins and Steroids","volume":"38","author":"Andreassen","year":"2006","journal-title":"Horm. Metab. Res."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Schaller, J. (2008). Human Blood Plasma Proteins: Structure and Function, Wiley Online Library.","DOI":"10.1002\/9780470724378"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"108907","DOI":"10.1016\/j.bioorg.2025.108907","article-title":"STAT3 Inhibitors Combined with Retinol Binding Protein 4 Complex Ameliorate DEN-Induced Liver Carcinogenesis in Mice and Induce Apoptosis via GRP78\/ATF6\/CHOP Signaling Pathway","volume":"165","author":"Wu","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.mce.2009.08.009","article-title":"Interactions of Sex Hormone-Binding Globulin with Target Cells","volume":"316","author":"Rosner","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.2217\/nnm-2020-0090","article-title":"Targeting Cancer with Lactoferrin Nanoparticles: Recent Advances","volume":"15","author":"Kondapi","year":"2020","journal-title":"Nanomedicine"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nature12138","article-title":"Macropinocytosis of Protein Is an Amino Acid Supply Route in Ras-Transformed Cells","volume":"497","author":"Commisso","year":"2013","journal-title":"Nature"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1158\/0008-5472.CAN-14-2211","article-title":"Human Pancreatic Cancer Tumors Are Nutrient Poor and Tumor Cells Actively Scavenge Extracellular Protein","volume":"75","author":"Kamphorst","year":"2015","journal-title":"Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"629","DOI":"10.4155\/tde.13.21","article-title":"Transferrin and the Transferrin Receptor for the Targeted Delivery of Therapeutic Agents to the Brain and Cancer Cells","volume":"4","author":"Somani","year":"2013","journal-title":"Ther. Deliv."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/jnr.490180206","article-title":"Receptor-Mediated Transcytosis of Transferrin across the Blood-Brain Barrier","volume":"18","author":"Fishman","year":"1987","journal-title":"J. Neurosci. Res."},{"key":"ref_139","first-page":"H1149","article-title":"Receptor-Mediated Transcytosis of Transferrin through Blood-Brain Barrier Endothelial Cells","volume":"270","author":"Descamps","year":"1996","journal-title":"Am. J. Physiol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.lfs.2005.05.085","article-title":"Pharmacokinetics and Brain Uptake of Lactoferrin in Rats","volume":"78","author":"Ji","year":"2006","journal-title":"Life Sci."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Marforio, T.D., Mattioli, E.J., Zerbetto, F., and Calvaresi, M. (2023). Exploiting Blood Transport Proteins as Carborane Supramolecular Vehicles for Boron Neutron Capture Therapy. Nanomaterials, 13.","DOI":"10.3390\/nano13111770"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41587-024-02127-0","article-title":"Machine Learning for Functional Protein Design","volume":"42","author":"Notin","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41580-024-00718-y","article-title":"Opportunities and Challenges in Design and Optimization of Protein Function","volume":"25","author":"Listov","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2101527","DOI":"10.1002\/adfm.202101527","article-title":"A Bio-Conjugated Fullerene as a Subcellular-Targeted and Multifaceted Phototheranostic Agent","volume":"31","author":"Seeger","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Islam, W., Niidome, T., and Sawa, T. (2022). Enhanced Permeability and Retention Effect as a Ubiquitous and Epoch-Making Phenomenon for the Selective Drug Targeting of Solid Tumors. J. Pers. Med., 12.","DOI":"10.3390\/jpm12121964"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s44222-024-00154-9","article-title":"The Mechanisms of Nanoparticle Delivery to Solid Tumours","volume":"2","author":"Nguyen","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jconrel.2022.03.043","article-title":"Strategies to Improve the EPR Effect: A Mechanistic Perspective and Clinical Translation","volume":"345","author":"Wang","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of Nanoparticle Delivery to Tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3106\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:13:27Z","timestamp":1790741607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":148,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193106"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193106","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]}}}